What is the most appropriate next step for a 34‑year‑old trans male patient presenting with insomnia, requesting a trazodone refill, disclosing a recent gender‑identity transition and desire for testosterone therapy, and appearing tense and preoccupied?

Immediate Assessment: Screen for Depression, Suicidality, and Underlying Causes of Insomnia

The most appropriate next step is to conduct a focused mental health assessment today, specifically screening for depression, suicidality, and other psychiatric conditions before addressing the trazodone refill request. The patient's tense and preoccupied presentation, combined with a major life transition (gender identity realization), warrants immediate evaluation for mood disorders and safety concerns 1.

Why Mental Health Screening Takes Priority

This patient presents with several red flags that require immediate attention:

• Tense and preoccupied appearance suggests possible underlying anxiety or depression
• Major identity transition within the past year—a period associated with increased mental health vulnerability
• Insomnia is frequently a symptom of depression, anxiety, or other psychiatric conditions rather than a primary disorder
• Request for trazodone (an antidepressant) may indicate previous depression treatment

The FDA labeling for trazodone explicitly warns about suicidal thoughts and behaviors, particularly requiring monitoring for "clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy" 1. Before prescribing or refilling this medication, you must assess baseline mental health status.

Specific Assessment Components for Today's Visit

1. Depression Screening

• Use a validated tool (PHQ-9) to quantify depressive symptoms
• Ask specifically about: anhedonia, hopelessness, worthlessness, concentration difficulties, energy level, appetite changes
• Assess duration and severity of symptoms

2. Suicide Risk Assessment

• Direct questioning is essential: "Are you having thoughts of harming yourself or ending your life?"
• If positive: assess plan, intent, access to means, protective factors
• This is non-negotiable before prescribing trazodone given FDA black box warnings 1

3. Insomnia Characterization

• Sleep onset vs. maintenance insomnia
• Duration and frequency (chronic insomnia requires ≥3 months, ≥3 times/week) 2
• Daytime consequences and functional impairment
• Sleep hygiene practices and environmental factors
• Rule out secondary causes: depression, anxiety, substance use, medical conditions, sleep apnea

4. Gender Transition-Related Stressors

• Social support system and acceptance
• Experiences of discrimination or harassment (28% of transgender individuals report harassment in clinical settings) 3
• Financial stressors related to transition
• Safety concerns in daily life

5. Substance Use

• Alcohol, cannabis, stimulants—all can contribute to insomnia
• Previous or current substance use disorders

Clinical Reasoning: Why Not Just Refill Trazodone?

While trazodone is commonly prescribed off-label for insomnia, recent guidelines do not support it as first-line therapy 4. The American Academy of Sleep Medicine 2017 guideline for chronic insomnia recommends cognitive-behavioral therapy for insomnia (CBT-I) as first-line treatment 2. Trazodone carries significant risks:

• Cardiac arrhythmias including QT prolongation and torsade de pointes (reported even at doses ≤100mg) 1
• Orthostatic hypotension and syncope 1
• Serotonin syndrome risk, especially with other serotonergic medications 1
• Daytime drowsiness (OR 2.53) and decreased appetite (OR 2.81) 5
• Withdrawal symptoms including anxiety, agitation, and sleep problems if discontinued abruptly 1

Appropriate Documentation and Chart Updates

Before addressing any clinical issues, update the electronic health record with the patient's affirmed gender identity, pronouns (he/him), and preferred name 3, 6, 3. This is not merely administrative—failing to use correct name and pronouns has been shown to negatively impact health outcomes and may lead to loss of patient retention 3. Document:

• Sex assigned at birth (female)
• Current gender identity (male/trans male)
• Affirmed name and pronouns (he/him)
• Organ inventory (relevant for future preventive care)

Decision Algorithm for Trazodone Refill

IF depression screening is positive (PHQ-9 ≥10):

• Trazodone may be appropriate as it treats both depression and insomnia
• Start at 50-100mg at bedtime 1
• Schedule follow-up in 1-2 weeks for safety monitoring
• Provide suicide prevention resources and emergency contact information

IF depression screening is negative but insomnia is chronic (≥3 months):

• First-line: Refer for CBT-I (strongest evidence for long-term benefit) 2
• If CBT-I unavailable or patient declines: Consider short-term trazodone (25-100mg at bedtime) while arranging CBT-I
• Trazodone showed significant improvement in total sleep time (+39.88 min), decreased sleep latency (-19.30 min), and increased deep sleep (N3) 5
• However, evidence quality is very low to moderate 5

IF insomnia is acute (<3 months):

• Address underlying causes (transition stress, anxiety)
• Sleep hygiene education
• Consider short-term trazodone (2-4 weeks) only if severe functional impairment
• Avoid long-term use without addressing root causes

Critical Safety Considerations Before Prescribing

Screen for contraindications to trazodone 1:

• Current MAOI use (absolute contraindication)
• History of cardiac arrhythmias or QT prolongation
• Recent myocardial infarction
• Concurrent use of QT-prolonging medications
• Baseline hematocrit >50% (less relevant but monitor if starting testosterone later)

Addressing the Testosterone Request

While you appropriately deferred the testosterone discussion to a future visit, acknowledge the patient's request positively today. State clearly: "I want to support your transition and we'll discuss testosterone thoroughly at our next appointment. Today, I want to make sure we address your sleep and overall well-being first." This validates his identity while maintaining appropriate clinical priorities.

Common Pitfalls to Avoid

1. Reflexively refilling trazodone without assessment—insomnia may be a symptom requiring different treatment
2. Ignoring the "tense and preoccupied" presentation—this is a clinical red flag requiring exploration
3. Failing to update pronouns and name in the chart—this creates safety risks and damages therapeutic alliance 3
4. Dismissing transition-related stress—transgender individuals face significant healthcare disparities and discrimination 7, 3
5. Prescribing trazodone long-term without attempting CBT-I—this contradicts current evidence-based guidelines 2

Follow-Up Plan

• Schedule 30-45 minute appointment in 1-2 weeks to discuss testosterone therapy comprehensively
• If trazodone prescribed today: follow up in 1-2 weeks to assess response and side effects
• If depression identified: consider whether testosterone should be delayed until mood stabilizes (though no absolute contraindication)
• Arrange CBT-I referral regardless of trazodone decision
• Connect patient with transgender-affirming mental health resources if needed